Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, Cabré E, Ojanguren I, Gassull M A
Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
Am J Gastroenterol. 1999 Apr;94(4):1053-6. doi: 10.1111/j.1572-0241.1999.01013.x.
It has been suggested that, in inflammatory bowel disease, cytomegalovirus behaves in the intestine as a nonpathogenic bystander, and even its finding in intestinal mucosa has unclear clinical relevance. We report our experience with a small series of patients with refractory inflammatory bowel disease and cytomegalovirus infection and their clinical outcome.
Nine patients with moderate-severe attacks of inflammatory bowel disease did not respond to i.v. prednisone (1 mg/kg/day) for a mean of 24 days. Four of these patients were further treated with i.v. cyclosporine A (4 mg/kg/day). Cytomegalovirus infection was diagnosed in two patients after resection for treatment failure. In the remaining patients, cytomegalovirus infection was diagnosed in endoscopic mucosal biopsies and i.v. ganciclovir was then administered at a dose of 10 mg/kg/day for 2-3 wk. Five of these patients went into clinical remission, allowing corticosteroid and cyclosporine A discontinuation. Follow-up biopsies were performed and in all cases cytomegalovirus could not be detected in the colonic tissue. Two patients needed to be treated with intravenous cyclosporine A after antiviral therapy because of persistence of clinical symptoms despite the elimination of cytomegalovirus infection.
Cytomegalovirus infection may play a role in the natural history of refractory inflammatory bowel disease and in some of its complications. The clearance of cytomegalovirus in colonic mucosa may lead some of these patients to remission.
有人提出,在炎症性肠病中,巨细胞病毒在肠道内表现为非致病性旁观者,甚至在肠道黏膜中发现它也具有不明确的临床相关性。我们报告了一小系列难治性炎症性肠病合并巨细胞病毒感染患者的经验及其临床结局。
9例中度至重度炎症性肠病发作患者对静脉注射泼尼松(1毫克/千克/天)平均治疗24天无反应。其中4例患者进一步接受静脉注射环孢素A(4毫克/千克/天)治疗。2例患者因治疗失败行切除术后被诊断为巨细胞病毒感染。其余患者在内镜黏膜活检中被诊断为巨细胞病毒感染,随后给予静脉注射更昔洛韦,剂量为10毫克/千克/天,持续2 - 3周。其中5例患者进入临床缓解期,得以停用皮质类固醇和环孢素A。进行了随访活检,所有病例的结肠组织中均未检测到巨细胞病毒。2例患者在抗病毒治疗后因尽管巨细胞病毒感染已消除但临床症状持续而需要接受静脉注射环孢素A治疗。
巨细胞病毒感染可能在难治性炎症性肠病的自然病程及其一些并发症中起作用。结肠黏膜中巨细胞病毒的清除可能使部分此类患者缓解。